{"id":"who-tbm-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL4577253","moleculeType":"Unknown","molecularWeight":"1365.47"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This is a clinical treatment protocol rather than a single drug entity, typically comprising isoniazid, rifampicin, pyrazinamide, and ethambutol with adjunctive corticosteroids. The regimen is designed to achieve adequate CNS penetration and bactericidal activity against TB while managing inflammation in the meninges. The Phase 3 trial likely evaluates efficacy, safety, and optimal dosing/duration for TBM management.","oneSentence":"WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:58.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculous meningitis (TBM)"}]},"trialDetails":[{"nctId":"NCT06293352","phase":"NA","title":"Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-08-08","conditions":"Prosthetic-joint Infection, Knee Infection, Arthroplasty Complications","enrollment":153},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT06811792","phase":"","title":"Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2010-01-01","conditions":"Tuberculous Meningitis","enrollment":837},{"nctId":"NCT04560179","phase":"PHASE1","title":"Inhaled Tobramycin in BPD","status":"COMPLETED","sponsor":"Erik Allen Jensen","startDate":"2022-03-22","conditions":"Bronchopulmonary Dysplasia","enrollment":27},{"nctId":"NCT06106789","phase":"","title":"A Study of the Clinical Benefit of Tobramycin Inhalation Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2023-04-01","conditions":"Bronchiectasis, Cystic Fibrosis, Lung Infection","enrollment":1600},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT01115582","phase":"PHASE3","title":"Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2010-04","conditions":"Inborn Errors of Bile Acid Synthesis","enrollment":16},{"nctId":"NCT05636254","phase":"","title":"Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2022-01-27","conditions":"Tuberculous Meningitis, Tuberculous Arachnoiditis","enrollment":120},{"nctId":"NCT03673956","phase":"PHASE1, PHASE2","title":"Topical Antibiotics in Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-26","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":19},{"nctId":"NCT01069705","phase":"PHASE3","title":"Second Open Label Extension to Bridging Study CTBM100C2303","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02-12","conditions":"Pulmonary Infections, Pseudomonas Aeruginosa","enrollment":49},{"nctId":"NCT00982930","phase":"PHASE3","title":"Open Label Extension to Bridging Study CTBM100C2303","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-08-12","conditions":"Pseudomonas Aeruginosa, Cystic Fibrosis","enrollment":55},{"nctId":"NCT02113397","phase":"","title":"Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2014-04","conditions":"Cystic Fibrosis","enrollment":1},{"nctId":"NCT02169882","phase":"PHASE2, PHASE3","title":"High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2014-12-01","conditions":"Tuberculosis, Meningeal","enrollment":60},{"nctId":"NCT01082367","phase":"PHASE3","title":"Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients","enrollment":50},{"nctId":"NCT00035425","phase":"PHASE3","title":"Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-11","conditions":"Febrile Neutropenia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard WHO treatment for TB meningitis"],"phase":"phase_3","status":"active","brandName":"WHO TBM treatment","genericName":"WHO TBM treatment","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system. Used for Tuberculous meningitis (TBM).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}